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Colorectal cancer is the third most common cancer (1) in the United States and Canada. In 2012, approximately 140 000 new patients were expected to be diagnosed in the United States (2) and 22 000 were expected in Canada (3) . Although curable when detected early, colorectal cancer is the second leading cause of cancer death in North America, resulting in approximately 58 000 deaths per year (1) . Recent improvements in the early diagnosis and treatment of colorectal cancer have led to increased survival (4) (5) (6) . However, changes in treatment, especially the use of new chemotherapeutic agents, have been linked to increased costs for care (7) . Given the high incidence and increased survival of colorectal cancer patients, it is beneficial for researchers, clinicians, and policy makers to characterize treatment receipt, identify populations of patients who do not receive optimal care, and quantify economic and health-care system resources needed to treat this growing population.
Although similar demographically, both with sizeable immigrant populations, the United States' multipayer system and Canada's universal single-payer system offer differing platforms to explore how patient treatment data are collected, managed, and used to measure care patterns. Comparisons across country and healthcare systems will allow the evaluation of different models of care delivery and can highlight issues regarding health-care practices and standards of care. In this systematic review of the literature, we describe patterns of care for patients diagnosed with colorectal cancer in the United States and Canada and evaluate data resources for capturing and measuring treatment patterns in both countries. Findings from this study may have implications for health-care delivery, treatment, and outcomes for patients diagnosed with colorectal cancer.
Methods
We used the MEDLINE database to identify articles on colorectal cancer care published in English between January 2000 and December 2010. Our search strategy combined the Medical Subject Heading (MeSH) term "Colorectal Neoplasms" with additional headings or text strings related to patterns of care, yielding 717 articles (see Appendix 1 for more details). Articles were hierarchically excluded for the following reasons: 1) the article did not report original research on receipt of colorectal cancer care; 2) the study was based on biological specimens, a nonhuman population, simulation model, or hypothetical cohort; 3) the study did not report receipt of cancer-directed initial care, postdiagnostic surveillance care, or end-of-life care; 4) the article reported results from a clinical study or controlled trial evaluating a specific treatment; 5) the study did not include information on patterns of care; 6) the study included fewer than 200 cancer patients; 7) the study did not report data for colorectal cancer care separately. After exclusions, we selected studies that were conducted in the United States or Canada. Studies conducted in Europe, Australia, and New Zealand are evaluated in a separate article (8) . The reference lists of the retained articles (n = 52) were examined to identify additional studies and were evaluated by the exclusion criteria described above. An additional 21 studies were identified from reference lists and a total of 73 studies are included in this systematic review of the literature.
For each article, we used a standard format to record cohort characteristics (ie, tumor site, stage, year of diagnosis or year of death in studies of end-of-life care, sample size, age distribution); health-care delivery setting and data sources used to identify patients and their health services (ie, cancer registry data, medical records, claims, surveys); and a summary of key findings on the receipt of care. Items were recorded as "Not Reported" if the information was not explicitly stated or could not be reasonably inferred from the summary statistics presented. Four reviewers participated in data abstraction. To ensure consistency between reviewers, we completed three quality control checks, where each reviewer abstracted the same three studies and compared abstracted findings.
With respect to patterns of colorectal cancer care, we abstracted the proportion of patients receiving specific types of initial care, postdiagnostic surveillance care, and end-of-life care. Cancer-directed initial care consisted of surgery, radiotherapy, chemotherapy, and multicomponent care where multiple types of care were reported together and could not be abstracted separately. The summaries of postdiagnostic surveillance and end-oflife care patterns are presented in the text only, given the small number of studies. We also documented patient population and health-care provider characteristics that were associated with receipt of care and whether the associations were positive or negative. These characteristics included patient sex, race and/or ethnicity, marital status, stage of disease at diagnosis, delivery setting, and provider practice patterns (eg, cancer patient volume). We reported patterns of care across the continuum of care from initial treatment following diagnosis to postdiagnostic surveillance and, finally, end-of-life care. When appropriate, we attempted to identify when care was guideline-concordant. In each table, studies are ordered by date of publication.
Results

Study Characteristics
Of the 73 studies included in this review (9-81), 62 were conducted in the United States and 11 were conducted in Canada (Table 1 ). The number of published articles on colorectal cancer care increased across the study period more rapidly in Canada, with a majority published between 2008 and 2010. Patterns of cancer-directed initial care represented the greatest number of studies for both the United States (76%) and Canada (82%), followed by studies on postdiagnostic surveillance care. Studies that reported end-of-life care were only identified in the United States (8%). With respect to cancer-directed initial care, nearly half of US studies reported on the receipt of chemotherapy (48%); in Canada, surgery, radiotherapy, and chemotherapy were assessed in similar proportions. Several studies that included a description of cancer-directed initial care fell into two or more categories used to describe "Type of care reported" or "Type of initial care reported." Thus, these two study characteristics were not mutually exclusive.
Most colorectal cancer patients and health services data were identified by registry data linked to medical records, insurance claims, or physician surveys in the United States (53%); in Canada, all studies were conducted using data of this type (100%). Registry data alone accounted for patient and health services information in 18% of US studies. The remaining data sources in the United States included medical claims alone (5%) or other data sources, including special studies designed to assess treatment receipt and outcomes for cancer patients (24%). In both countries, similar numbers of studies assessed treatment for colon, rectal, and colorectal tumors, where "colorectal tumors" describe studies that assessed both colon and rectal tumor sites together and could not be abstracted separately. Several studies assessed two or more tumor sites; thus, our cohort characteristic titled "Tumor site reported" is not mutually exclusive. Several studies were represented across multiple tables or multiple times within a single table. In the United States, the majority of studies included 5000 or more patients. And in Canada, all study populations included less than 5000 patients. Health services data sources for the United States and Canada are described in Tables 2 and 3 .
Cancer-Directed Initial Care-Surgery, Radiotherapy, Chemotherapy, and Multicomponent Care The receipt of surgical care for colorectal cancer was reported in 16 US studies and 4 Canadian studies (Table 4) . Health services data were obtained from a variety of sources, including state or provincial registries with or without linkage to medical claims or patient records, hospital discharge data (eg, the Healthcare Cost and Utilization Project [HCUP]), or the National Cancer Data Base. Study cohorts were drawn from single institutions and national-, state-, or provincial-based populations. Most studies reported receipt of surgery near or above 80% in both the United States and Canada. Surgery as the sole treatment modality decreased across time, giving way to treatment plans that included neoadjuvant or adjuvant therapy (13, 31) . Older and uninsured patients had the highest proportions of emergency resections (23) , and several studies reported an increasing trend over time for the proportion of rectal cancer patients receiving sphincter-sparing surgery. Surgery receipt varied by anatomical location of the tumor, race, sex, and age.
Twenty-one studies reported patterns of care for the receipt of radiotherapy in the United States and Canada (Table 5) . Surveillance, Epidemiology, and End Results (SEER) registries alone or linked to Medicare claims were used to identify radiotherapy receipt for a plurality of US studies. Similarly, all studies of radiotherapy use in Canada obtained data from provincially based cancer registries augmented by treatment data from medical records (ie, CancerCare Manitoba and the British Columbia Cancer Agency). Patients with stage II-III, local, or regional rectal cancer had the greatest representation within studies of radiotherapy; for this subset, rates of radiotherapy use increased from approximately 15% in the mid-1970s to 50% or greater in the first decade of the 21st century. This upward trend was evident in both Canada and the United States (13, 35) and is in accordance with findings from randomized controlled trials that have demonstrated survival benefits from the use of radiotherapy in the treatment of early-stage rectal cancer (82) .
Patterns of care for the receipt of chemotherapy were reported in 29 US studies and 5 Canadian studies (Table 6 ). SEER-Medicare or state registry data linked to Medicare claims provided treatment information for a majority of studies in the United States. The remaining US studies obtained data through hospital registries, a health maintenance organization (HMO) insurance network, or special studies of cancer patients (eg, the National Comprehensive Cancer Network's (NCCN) Colon/Rectum Cancer Outcomes Database). As in other studies of initial care for Canada, chemotherapy treatment data were obtained from provincial registries linked to supplemental data sources. Several methods and definitions were used to assess chemotherapy receipt, even within studies, yielding a wide range of estimates. In the United States, lower use of chemotherapy was observed among patients with Medicaid coverage and those with comorbidities. And although black and white patients received consultation with an oncologist in similar proportions, white patients were significantly more likely to receive chemotherapy compared with black patients (34, 50) .
Seventeen studies reported receipt of multicomponent care for the treatment of colorectal cancer in the United States or Canada (Table 7) . Among studies that referenced published guidelines for the receipt of adjuvant therapy, adherence ranged between approximately 50% and 80%. Patients and health services data were identified from various sources, including SEER Patterns of Care, the National Cancer Data Base, and provincial registries in Canada.
Postdiagnostic Surveillance Care
Patterns of care for the postdiagnostic surveillance of colorectal cancer were reported in 13 studies and were most commonly discussed in the context of achieving various guideline recommendations. Eleven studies were conducted in the United States (52, (66) (67) (68) (69) (70) 74, (77) (78) (79) 81) and two studies were conducted in Canada (65, 72) . SEER-Medicare data were used to assess postdiagnostic surveillance for a majority of the US studies. Data for the remaining studies in both the United States and Canada were obtained however, a significant difference in treatment receipt was observed where 70% of whites and 60% of blacks received chemotherapy (P < 0.001) Because various established guidelines were used to evaluate adherence to postdiagnostic surveillance at varying time points following initial treatment, studies reported disparate proportions for receipt of care. In the United States, receipt of surveillance care ranged between 26% and 83% for bowel or colon examinations, and between 60% and 92% for physician office visits. In Canada, 59% to 71% of patients received CEA testing compared with 47% of patients in a US population (65, 66) . The use of scans for colorectal cancer surveillance has not been included in any published guidelines at the time of this publication; however, US studies reported 7% to 59% for the use of X-ray or positron emission tomographic scans. Receipt of surveillance care was independently associated with race, age, and treatment facility; blacks, older patients, and patients treated in community vs teaching hospitals were less likely to receive care (65, 69, 77) .
End-of-Life Care
Five studies reported the receipt of end-of-life care for colorectal cancer patients (71, 73, 75, 76, 80) . These studies were all conducted in the United States and evaluated the use of palliative chemotherapy, hospice care, and hospital or emergency room services. 
Discussion
In this study, we evaluated contemporary patterns of colorectal cancer care in the United States and Canada, as identified through a systematic review of 73 studies. Although direct comparisons between and within the two countries were limited by differences in study populations and research methods, we generally observed similar patterns of cancer-directed initial care, including rates of surgical treatment, use of adjuvant chemotherapy, and use of radiation therapy in the United States and Canada. Few studies measured postdiagnostic surveillance or end-of-life care. Our findings highlighted research gaps related to treatment practices in the absence of consensus-based guidelines. In addition, the time required to link data sources used to measure patterns of care results in data lags that can affect promising research, as in the case of the SEER-Medicare linkage (83) . Researchers, clinicians, and policy makers can use findings from this review in efforts to quantify future economic and health-care resources that will be needed to improve treatment, outcomes, and access to care for colorectal cancer patients treated in the United States and Canada.
Findings for cancer-directed surgery in both the United States and Canada showed that most patients were resected, although the specific types of surgery received varied. Since 2000, surgical resection as the sole treatment modality for any colorectal cancer has declined with the addition of neoadjuvant and adjuvant treatment. In recent years, permanent colostomies have occurred less frequently and sphincter-sparing procedures have become a viable option for more rectal cancer patients when radiotherapy is given preoperatively (84) . Moreover, the role of radiotherapy among colorectal cancer patients is largely restricted to those with rectal cancer. For these patients, the use of radiotherapy increased over time, whereas rates for colon cancer patients remained stagnant at 20% or less (27, 29) . This observation is consistent with recommendations for the treatment of colorectal cancer (85), which endorse radiotherapy for patients with rectal cancer, specifically those with stage II or III disease. In contrast, receipt of radiotherapy is only indicated for stage IV colon cancer patients or those who have experienced recurrence. The receipt of neoadjuvant radiotherapy for rectal cancer patients also increased over time (31) . Shrinking the tumor preoperatively through neoadjuvant therapy maximizes options for surgical resection and is likely to affect observed patterns of both surgical and adjuvant care.
Receipt of chemotherapy increased over time, but varied considerably across studies, ranging between 28% and 90% in the United States and between 0% and 92% in Canada. Chemotherapy receipt was associated with anatomical site of the tumor, stage of disease, and patient insurance status; such wide variation in treatment receipt was due to differences in study populations and research methods. For US and Canadian studies that had comparable patient populations, receipt of chemotherapy was generally similar. Among those receiving chemotherapy, 5-Fluorouracil (5-FU)-based regimens were commonly administered, particularly for patients with stage II-IV colon cancer where such treatment is recommended by guidelines (85) . However, with the advent of effective but expensive drugs (86) and use of supportive agents (87) , costs associated with chemotherapy are expected to increase over time, potentially introducing an additional barrier for patients to receive appropriate care. Few studies in our review addressed the use of newer chemotherapeutic or biological agents, due, in part, to lags in the availability of data on cancer drugs. Future research should evaluate the specific agents used in colorectal cancer care.
Consensus-based guidelines provided the context for many of the studies that assessed multicomponent care in our review; however, guideline adherence varied by study population setting and year of diagnosis, likely because practice guidelines vary in their treatment recommendations. One study assessing treatment in relation to NCCN guidelines among a network of NCCN institutions reported that although guideline adherence varied, the reported receipt of guideline care remained high (>80%), as may be expected among US comprehensive cancer centers (32) . In contrast, a population-based study conducted by Shroen et al. demonstrated that only 44% of stage II and 60% of stage III rectal cancer patients obtained recommended therapy, as outlined by the National Institutes of Health Consensus Conference (21) .
Comparisons of treatment receipt between and within the United States and Canada are limited for early-and late-stage colorectal cancer patients because of the lack of consensus-based guidelines for the two patient groups. Nearly 40% of colorectal cancer patients receive a diagnosis of localized disease, and approximately one-quarter of patients are diagnosed with distant disease. This results in a substantial number of patients whose treatment plans cannot be evaluated in relation to a standard of care (88) . Controlled trials for these patient populations will play a large role in guideline development. However, it should be noted that treatment plans vary at the discretion of the treating physician along with patient preferences for care, despite the existence of guideline recommendations.
Few studies of postdiagnostic surveillance were identified for our review, and most were conducted in the context of achieving guideline recommendations. Because there was no general consensus on frequency and time to follow-up care across guidelines, proportions of care receipt varied widely. Coordinated development of evidence-based guidelines for postdiagnostic colorectal cancer surveillance is needed to improve patient care, and evaluation of their implementation will be important for future research.
Few studies in our literature review addressed end-of-life care for colorectal cancer patients. This is may be expected because end-of-life studies tend to group all cancer patients together and do not report receipt of care separately by cancer site. However, because palliative care is not cancer-directed, this component of end-of-life care may be relatively consistent for all cancer patients. Of the five end-of-life care studies we identified, four were conducted among US patients with Medicare coverage, which promotes the use of hospice care. Future research describing end-of-life care will be important, particularly in Canada, where we did not identify any study and where the availability of hospice care varies by province.
A significant proportion of patients did not receive expected surgical or adjuvant care based on tumor site and disease stage, particularly patients who were nonwhite, older age, or who reported comorbidities. In the United States, blacks were least likely to receive any component of colorectal cancer care. However, we identified particularly worrisome findings in our review for chemotherapy use in the context of disparities by race. Although black and white colon cancer patients received consultation with an oncologist in similar proportions, blacks were significantly less likely to receive chemotherapy (34, 50) . The Canadian studies included in our review generally did not provide data on treatment receipt stratified by race. Studies assessing the association between race and treatment receipt in Canada's universal health-care system would add to the current body of knowledge regarding disparities in health-care access because barriers to care are assumed to be mitigated in this population. In the United States, more studies of Asian and Hispanic populations, which were underrepresented in our review, are needed to inform efforts that seek to improve care. Older patients and individuals with comorbidities were also consistently less likely to obtain recommended care (36, 45, 47, 61) . However, these patient populations typically have contraindications to treatment; thus, data on performance status in future research will allow for improved assessments of patterns of care. Ongoing efforts to improve measurement of comorbidities and to evaluate potential barriers of access to care will inform future efforts to reduce treatment disparities.
Though trends in the receipt of care were generally similar between the two countries, we observed differences in the United States and Canada with respect to data resources used to identify colorectal cancer treatment. Health-care payers in each country are central to the availability of patient treatment data. Canada's universal health coverage provides centralized systems health services data, thereby creating a potential resource that would allow for the continuous observation of patients. However, few provinces or territories have linked registry data to insurance claims. In the United States, varying forms of health-care coverage yield multiple data sources that can be used to measure patterns of care. But the disparate resources pose a challenge in the accurate assessment of care patterns for the US population as a whole. Additionally, measuring patterns of care is limited by discontinuity between data sources and lags in data availability for both countries. In the United States, ongoing state-based efforts to link registry data with multiple health insurance datasets may lead to a more comprehensive view of cancer care patterns (89) (90) (91) . In Canada, the Canadian Partnership Against Cancer (CPAC) heads several initiatives that seek to improve cancer surveillance, including efforts to reduce information gaps at the national, provincial, and territorial levels (92) .
In conclusion, this review summarizes a substantial volume of literature on colorectal cancer treatment practices in the United States and Canada, providing a basis for researchers who seek to address research gaps within colorectal cancer populations. Future work in assessing patterns of care for colorectal cancer patients in the United States and Canada should seek to include more studies in the areas of postdiagnostic surveillance and end-of-life care, which were both underrepresented in our review. Although guidelines provide insight on specific aspects of care, ongoing evaluation of the receipt of all types of colorectal cancer care for all stages and tumor sites will be important in identifying over-and underuse of health services. Further, where guideline consensuses do not exist, as in the case of postdiagnostic surveillance care, descriptions of metrics used to assess receipt of care will enable comparisons across studies. Future work should also address challenges to the interpretation of care patterns, including the use of various staging systems, alternating use of clinical or pathological staging, and contraindications to treatment that are not consistently captured or are absent from data sources. High-quality research on patterns of colorectal cancer care will aid policy makers in quantifying the resources needed to treat this population, while addressing disparities, projecting future costs, and ultimately improving care and cancer outcomes.
